T A B L E O F C O N T E N
1. all cause mortality, CHF-related admission to hospital, all-cause readmissions to hospital and length of stay and; 2. quality of life, healthcare cost savings in patients with CHF.
The cost of the intervention and acceptability of the intervention to patients will also be examined.
B A C K G R O U N D Description of the condition
Chronic heart failure (CHF) is a complex, debilitating syndrome which is the consequence of structural abnormality or cardiac dysfunction that impairs the ability of the ventricle to fill with, or eject blood. As a result typical symptoms such as dyspnoea and fatigue occur at rest or with physical effort. CHF often results from damage to the myocardium for which the aetiology differs according to the population studied. In high income nations CHF is often the end-product of underlying coronary heart disease. In low to medium income nations the syndrome is often the result of longstanding hypertension, cardiomyopathy or rheumatic heart disease (Sliwa 2005). This trend is changing, with the incidence and prevalence of cardiovascular disease increasing in low to medium income nations (Yusuf 2001). CHF exerts a significant burden on healthcare systems, with the majority of its economic burden attributable to repeated and lengthy admissions to hospital (Stewart 2002). As the prevalence of CHF increases with the ageing of populations internationally, this situation will deteriorate unless new management strategies are developed (Cleland 2000).
Description of the intervention
The effectiveness of multidisciplinary non-pharmacological approaches to manage patients with CHF has been proven by metaanalyses, such as that conducted by Taylor To date, trials of specialist, multidisciplinary CHF management programmes have tested multifaceted approaches (home/clinic visits, telephone support). As a consequence it has been difficult to identify the incremental benefits of the components of each intervention (McAlister 2004) . Nevertheless, it is clear that within most populations access to these programmes is limited as a result of barriers related to funding or geography (Clark 2007a; Jaarsma 2006). To meet the needs of CHF populations who are distal to traditional home or clinic-based CHF disease management programmes, alternative models of care have been proposed and tested (Clark 2007a). These alternative models typically involve information communication technology (ICT) and may include telemonitoring (transfer of physiological data via digital cable e.g. electrocardiograph (ECG), blood pressure (BP), weight, pulse oximetry (SPO2) respiratory rate and medicine administration) or structured computer-assisted education and monitoring delivered via standard telephone or videoconferencing (Clark 2007b). These remote monitoring programmes may allow patients who can not or do not wish to be visited at home, or those that are unable to attend a clinic or do not have local access to traditional CHF management programmes, to receive the best practice for non-pharmacological management of CHF. It should be noted that in the context of this review "remote monitoring" will be defined as monitoring CHF patients outside of a CHF specialist centre of care and not remote in the geographical sense, although these patients are often one in the same group. In all studies of structured telephone support, having access to a touch-tone telephone was an essential inclusion criteria. In the case of telemonitoring the ICT equipment and monitoring devices are provided by the project. Patients from socio-economically disadvantaged groups would have been excluded if they did not have access to a basic telephone in their place of residence.
Why it is important to do this review
In this era of rapidly advancing technology and wider community access and adaptation to ICT, new trials of remote monitoring interventions are continually being commissioned and published. Previous systematic reviews and meta-analyses 
O B J E C T I V E S
The objective of this study is to update the review previously completed by Clark 2007b and assess systematically the effects of telemonitoring and/or structured telephone support programmes on:
1. all cause mortality, CHF-related admission to hospital, allcause readmissions to hospital and length of stay and; 2. quality of life, healthcare cost savings in patients with CHF.
M E T H O D S Criteria for considering studies for this review Types of studies
Randomised controlled trials or controlled trials (that is studies in which a contemporaneous comparison group is identified but in which random allocation to intervention or comparison group was not performed) comparing CHF management delivered via structured telephone support and/or telemonitoring with usual postdischarge care in patients with CHF living within the community.
Studies will be included in the analyses regardless of whether they are single-blind, double-blind or not blinded.
Types of participants
Adult (aged 18+ years) of either sex, any age or ethnic group with definitive diagnosis of CHF discharged from an acute care setting (including emergency departments and one-day-stay procedures) to home (including a relative's home but excluding nursing homes or convalescence homes). Studies dealing generally with cardiac disorders but not specifically denoting CHF will be excluded.
Types of interventions
Structured telephone support and/or telemonitoring interventions need to be structured as opposed to offering telephone follow-up on an "as needed" basis. They must be initiated by a healthcare professional (medical, nursing, social work, pharmacist) and delivered to patients with CHF living in the community as the only aftercare intervention, without home visits or more than usual clinic follow-up.They must be performed at least once within the first 28 days following discharge from hospital, they must be targeted towards the patient, and intended to address the patients concerns and problems not those of caregivers. Usual care will consist of standard post-discharge care without regular attendance at a clinic-based CHF disease management programme or any visits at home by a specialised CHF healthcare professional.
Types of outcome measures Primary outcomes
• All-cause mortality (total number of deaths at the end of study follow-up in each arm of the study).
Secondary outcomes
• All-cause hospitalisation rate (calculated as the proportion of patients readmitted to hospital at least once during the period of follow-up).
• Chronic heart failure-related hospitalisation rate (calculated as the proportion of patients readmitted to hospital at least once during the period of follow-up due to chronic heart failure).
• Length of stay (total number of days in hospital accumulated by each study group)
• Health-related quality of life (difference between mean total score on validated measures such as Minnesota Living with Heart Failure Questionnaire between baseline and at study conclusion for the intervention and control groups).
• Cost of the intervention, costs savings (reported cost of the intervention; reported difference in the cost of medical care during the course of the study between the intervention and control groups).
• Acceptability of the intervention to patients (difference between acceptability/satisfaction scores on a Likert scale at study conclusion between the intervention and control groups).
Search methods for identification of studies Electronic searches
The following databases will be searched, from 7 May 2006 forwards to update the search performed for from the previous review (Clark 2007b): Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library; MEDLINE; EMBASE; CINAHL; AMED; Science Citation Index Expanded; DARE; National Research Register. No date limits will be applied to the searches of the following databases; IEEE Xplore; OAIster; Google Scholar; Informit; Vivisimo; Australian Digital Theses Program and Proquest Digital Dissertations. Language restrictions will not apply. Details of the strategies for searching these electronic databases are in Appendix 1.
Searching other resources
Bibliographies of identified studies and published systematic reviews relevant to this topic area will be hand searched. National and international experts in the field will be contacted to identify published and/or unpublished trials.
Data collection and analysis

Selection of studies
Two investigators will independently review the results of each search according to exclusion and inclusion criteria. Studies will be excluded if there are additional home or clinic visits (more than usual care) offered to patients in the intervention or control groups. A third reviewer will adjudicate in the instance of indecision by the first two reviewers.
Data extraction and management
Two reviewers will abstract the data from the included studies in a blinded manner and all extracted data will be checked by a third reviewer.
Assessment of risk of bias in included studies
In consideration of Cochrane methodology (Higgins 2006) study quality will be assessed independently by two reviewers. The study quality characteristics will be rated as (1) unclear or not stated; (2) inadequate; (3) adequate with examples from the text to support this classification. Adequacy and inadequacy of each of the study quality parameters will be defined as follows.
Inclusion criteria of the included participants
The definition and confirmation of diagnosis of CHF.
• Adequate -LVEF< 40%, a diagnosis of CHF (systolic or preserved) recorded
• Inadequate -LVEF >40% or ventricular dysfunction not classified
Generation of the randomisation sequence
• Adequate -random permuted blocks, random computer generated, sealed assignment, sequentially numbered sealed opaque envelopes.
• Inadequate -case record numbers, date of birth or days of the week.
Allocation concealment
• Adequate -allocation to each group performed adequately and group assignment revealed after provision of consent.
• Inadequate -group assignment revealed prior to subject consent, non-opaque sealed envelopes, case record numbers, date of birth or day of the week.
Baseline comparability of the groups
• Adequate -the baseline characteristics of each study group (in particular age, NYHA Class and/or LVEF) is clearly outlined and any differences identified are accounted for.
• Inadequate -baseline characteristics (in particular age, NYHA Class and/or LVEF) of each study group are not outlined.
Blinding
Focused on outcomes assessors and data analysts, it is not considered plausible that patients could be blinded to these types of interventions).
• Adequate -independent outcome assessors and data analysts who are blinded to which group the patient belongs to.
• Inadequate -outcomes assessed and data analysed by those involved in the intervention, or those who are aware of group membership.
Completeness of follow up
• Adequate -proportion and characteristics of those participants lost to follow up clearly reported for each group and outcome. A clear outline is provided as to how losses of participants were handled.
• Inadequate -proportion and characteristics of those completing and not completing the study according to group and outcome not reported. No statement regarding how losses to follow up were accounted for in the study analysis.
Statistical power
• Adequate -a power calculation was performed and reported. The study was adequately powered to detect differences in outcomes.
• Inadequate -a power calculation was not performed. A power calculation was performed and reported but the study was not adequately powered to detect differences in outcomes. A power calculation was performed but not reported, the study states it was adequately powered to detect differences in outcomes.
Risk of bias (selection, performance, detection and attrition)
Risk of bias will be identified for each included study and tabulated according to the following headings.
• Type of bias.
• Definition of the type of bias relevant to these types of studies and interventions.
• Example from text suggesting a possible source of bias.
• Comment on how this potential source of bias my have influence the study outcomes.
• Overall judgement on the importance of this identified potential source of bias on study quality and validity.
Measures of treatment effect
Risk ratios and 95% confidence intervals will be calculated for allcause mortality, all-cause and CHF-related hospitalisation rates. All analyses will be performed according to intention-to-treat principles, that is, all patients and their outcomes will be analysed in the groups to which they were allocated, regardless of whether they received the treatment. Should there be sufficient reporting of continuous outcomes such as quality of life measured by Minnesota Living with Heart Failure Questionnaire these will be pooled and analysed accordingly. If there is infrequent or inconsistent reporting of these outcomes these will be tabulated and described.
Assessment of heterogeneity
Statistical heterogeneity in each outcome of interest will be examined using Cochran's Q test and I 2 statistic.
Data synthesis
Owing to expected differences in patient populations, programme characteristics, and length of follow-up, a Der Simonian and Laird random effects model will be used to perform the meta-analysis.
Sensitivity analysis
A sensitivity analysis will be performed according to severity of CHF (i.e. NYHA Class I and II versus III and IV) of included participants. Another sensitivity analysis will examine the inclusion criteria of the studies, comparing those which reported an adequate classification of CHF diagnosis (i.e. left ventricular ejection fraction (LVEF)) relative to those which only stated "patients with CHF". Our team wishes to make special acknowledgement to the contribution of the University of South Australia's Health Sciences Librarian, Ms Margaret Goedhart. Margaret's knowledge and skill in navigating current bibliographies and electronic sources of knowledge was essential to ensuring quality and rigor of the search strategies. 
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